for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vericel Corp

VCEL.OQ

Latest Trade

15.50USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

10.51

 - 

21.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
15.50
Open
--
Volume
--
3M AVG Volume
10.19
Today's High
--
Today's Low
--
52 Week High
21.00
52 Week Low
10.51
Shares Out (MIL)
44.14
Market Cap (MIL)
684.12
Forward P/E
-47.21
Dividend (Yield %)
--

Latest Developments

More

Vericel Reports Second Quarter 2019 Financial Results And Raises Full Year 2019 Revenue Guidance

Vericel Q1 Loss Per Share $0.07

Vericel Has Entered Into Exclusive License And Supply Agreements With Mediwound To Commercialize Nexobrid® In North America

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vericel Corp

Vericel Corporation is an integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of cellular therapies for use in the treatment of specific diseases.. Its autologous cell therapy products include Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Industry

Biotechnology & Drugs

Contact Info

64 Sidney St

+1.734.9305555

https://vcel.com/

Executive Leadership

Robert L. Zerbe

Independent Chairman of the Board

Dominick C. Colangelo

President, Chief Executive Officer, Director

Gerard J. Michel

Chief Financial Officer, Vice President - Corporate Development

Michael Halpin

Chief Operating Officer

Steven C. Gilman

Independent Director

Key Stats

1.50 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-1.060

2017

-0.490

2018

-0.200

2019(E)

-0.328
Price To Earnings (TTM)
--
Price To Sales (TTM)
6.72
Price To Book (MRQ)
7.71
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.19
LT Debt To Equity (MRQ)
0.15
Return on Investment (TTM)
-16.77
Return on Equity (TTM)
-14.89

Latest News

Latest News

BRIEF-Vericel Q4 Revenue Rose 41 Pct To $23.4 Mln

* VERICEL REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES FULL YEAR 2018 FINANCIAL GUIDANCE

BRIEF-Vericel Initiates Collaboration with Innovative Cellular Therapeutics   

* VERICEL CORP - INITIATION OF LICENSE AGREEMENT WITH INNOVATIVE CELLULAR THERAPEUTICS FOLLOWING RECEIPT OF $5.1 MILLION UPFRONT,WARRANT PAYMENT FROM ICT

BRIEF-Vericel Enters Into Expanded $25 Million Debt Facilities With Silicon Valley Bank And Midcap Financial

* VERICEL ENTERS INTO EXPANDED $25 MILLION DEBT FACILITIES WITH SILICON VALLEY BANK AND MIDCAP FINANCIAL TO SUPPORT ACCELERATING MACI UPTAKE AND INCREASED EPICEL USAGE

BRIEF-Vericel reports Q3 loss per share $0.16

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

BRIEF-‍Archon Capital Management reports a 7.56 pct passive stake in Vericel

* Archon Capital Management LLC reports a 7.56 pct passive stake in Vericel Corp of August 23 - SEC filing Source text: (http://bit.ly/2vxJQCK) Further company coverage:

BRIEF-Shanghai Pharmaceuticals Holding to bid for US firm Arbor

* Says it plans to bid for stake in U.S. specialty drug maker Arbor, clarifies media report

BRIEF-Vericel Q2 loss per share $0.07

* Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Vericel Corp enters distribution agreement with Orsini Pharmaceutical Services

* Co entered distribution agreement with Orsini Pharmaceutical Services Inc to appoint Orsini as specialty pharmacy distributor of Carticel

BRIEF-Vericel receives FDA regenerative medicine advanced therapy designation for Ixmyelocel-T

* Vericel receives FDA regenerative medicine advanced therapy (RMAT) designation for Ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy Source text for Eikon: Further company coverage:

BRIEF-Vericel Q1 loss per share $0.31

* Q1 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S

BRIEF-Vericel enters into license agreement with Innovative Cellular Therapeutics

* Vericel Corp - entered into a license agreement with Innovative Cellular Therapeutics for development, manufacturing and commercialization of Vericel product portfolio

BRIEF-Vericel Q4 loss per share $0.34

* Vericel reports fourth-quarter and year-end 2016 financial results

BRIEF-Vericel receives FDA fast track designation for ixmyelocel-T

* Vericel receives FDA fast track designation for ixmyelocel-T, an investigational product for the treatment of patients with advanced heart failure due to ischemic dilated cardiomyopathy Source text for Eikon: Further company coverage:

BRIEF-Vericel announces first MACI implant in U.S.to treat symptomatic cartilage defects of knee

* Vericel announces first MACI implant in United States for treatment of symptomatic cartilage defects of knee Source text for Eikon: Further company coverage:

BRIEF-Vericel signs agreement for data reporting services, to purchase, bill and collect from certain payers for Carticel

* Vericel - distribution, services agreement with Sartin's Vital Care., D/B/A Sartin's Vital Care, Burnham's Vital Care, L.L.C., D/B/A Burnham's Vital Care

BRIEF-LiveRamp announces acquisition of Arbor and Circulate

* Acxiom Corp says in addition, company will issue $50 million of Acxiom stock awards replacing unvested equity.

BRIEF-Vericel reports Q3 loss per share $0.38

* Q3 revenue $10.9 million Source text for Eikon: Further company coverage:

BRIEF-Vericel enters into sales agreement to sell co's common stock having aggregate sale price up to $25 million

* Vericel - entered sales agreement to sell co's common stock having aggregate sale price up to $25 million , through an at the market offering program Source text (http://bit.ly/2dsSVmY) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up